SPCs in the spotlight: Court of Justice of the EU rules in Neurim on Thursday
The Court of Justice of the EU will rule in a dispute between Neurim Pharmaceuticals and the UK Intellectual Property Office on Thursday, clarifying whether pharmaceutical companies can obtain supplementary protection certificates (SPCs) for second medical use patents. Here’s the background to the case
Click here for the latest on this story.
How it began
At the end of 2009, a hearing officer at the UKIPO refused an SPC for its product Ciracadin (melatonin). Circadin is used to treat insomnia and the basic patent...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.